Verona Pharma PLC Director/PDMR Shareholding (7827D)
April 28 2017 - 12:40PM
UK Regulatory
TIDMVRP
RNS Number : 7827D
Verona Pharma PLC
28 April 2017
Verona Pharma Announces Director Purchases and Related Party
Transactions
April 28, 2017, LONDON - Verona Pharma plc (AIM: VRP) ("Verona
Pharma"), a clinical-stage biopharmaceutical company focused on
developing and commercialising innovative therapeutics for the
treatment of respiratory diseases with significant unmet needs,
makes the following announcement further to the announcement
released yesterday in respect of the Global Offering and the
Shareholder Private Placement. Capitalised terms in this
announcement will have the same meanings to those defined in the
announcement released yesterday regarding the Global Offering,
unless otherwise indicated.
Director Purchases
Verona Pharma notifies the following transactions by persons
discharging managerial responsibilities ("PDMRs") in its ordinary
shares through participation in the Global Offering or, in the case
of Dr David Ebsworth, the Shareholder Private Placement.
Name No. of ADSs to be No. of ordinary shares Total Total number of ordinary
purchased to be purchased consideration shares or ADSs held
following closing
Dr David Ebsworth - 13,373 GBP17,652.36 117,657
(ordinary shares)
Vikas Sinha 22,222 - $299,997.00 22,222
(ADSs)
The notification of dealing form for each PDMR can be found
below.
AIM Rule 13 - Related Party Transactions
Verona Pharma has been informed that certain persons who are
related parties as defined in the AIM Rules for Companies (the "AIM
Rules") will be purchasing ADSs or ordinary shares in the Global
Offering. The participation of the following persons in the Global
Offering, by virtue of their each owning over 10% of the current
issued share capital of Verona Pharma and their respective
participations in the Global Offering, each constitutes a related
party transaction for the purposes of the AIM Rules.
The independent directors for the purposes of the Global
Offering (being all the Directors save for those connected to these
organisations participating in the Global Offering as detailed
below), having consulted with the Company's nominated adviser, N+1
Singer, consider that the terms of the related party transactions
are fair and reasonable in so far as Verona Pharma's shareholders
are concerned.
Name No. of ADSs to be purchased No. of ordinary shares to be Total consideration
purchased
Novo A/S 740,740 - $9,999,990.00
Funds affiliated with Vivo
Ventures 704,225 - $9,507,037.50
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction. Securities may not be o ered or sold in the United
States absent registration or an exemption from registration under
the United States Securities Act of 1933, as amended (the
"Securities Act"). Any public o ering of securities to be made in
the United States will be made by means of a prospectus. Such
prospectus will contain detailed information about the issuer and
its management and nancial statements. This press release is being
issued pursuant to and in accordance with Rule 135e under the
Securities Act.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
N+1 Singer (Nominated Adviser and UK Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / James White
FTI Consulting (UK Media and Investor Tel: +44 (0)20 3727 1000
enquiries)
Simon Conway / Stephanie Cuthbert / veronapharma@fticonsulting.com
Natalie Garland-Collins
ICR, Inc. (US Media and Investor enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
The following disclosure is made in accordance with Article 19
of the EU Market Abuse Regulation 596/2014.
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- ----------------------------------------------------------------
a) Name Dr David Ebsworth
--- ------------------------------ --------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Non-Executive Chairman
--- ------------------------------ --------------------------------
b) Initial notification Initial Notification
/Amendment
--- ------------------------------ --------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- ----------------------------------------------------------------
a) Name Verona Pharma plc
--- ------------------------------ --------------------------------
b) Legal Entity Identifier 213800EVI6O6J3TIAL06
--- ------------------------------ --------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description of the Ordinary Shares of 5p each
financial instrument,
type of instrument
---
Identification code ISIN Code: GB00BYW2KH80
--- ------------------------------ --------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
--- ------------------------------ --------------------------------
c) Price(s) and volume(s) Price Volume
--------- -------
GBP1.32 13,373
--------- -------
--- ------------------------------ --------------------------------
d) Aggregated information N/A (single transaction)
- Aggregated volume
- Price
--- ------------------------------ --------------------------------
e) Date of the transaction 26 April 2017
--- ------------------------------ --------------------------------
f) Place of the transaction London Stock Exchange, AIM
--- ------------------------------ --------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- ------------------------------------------------------------------------
a) Name Vikas Sinha
--- -------------------------- --------------------------------------------
2 Reason for the notification
--- ------------------------------------------------------------------------
a) Position/status Director
--- -------------------------- --------------------------------------------
b) Initial notification Initial Notification
/Amendment
--- -------------------------- --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- ------------------------------------------------------------------------
a) Name Verona Pharma plc
--- -------------------------- --------------------------------------------
b) Legal Entity Identifier 213800EVI6O6J3TIAL06
--- -------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- ------------------------------------------------------------------------
a) Description of the American Depositary Shares (each American
financial instrument, Depositary Share represents eight Ordinary
type of instrument Shares of 5p each in Verona Pharma plc)
---
Identification code ISIN Code: US9250501064
--- -------------------------- --------------------------------------------
b) Nature of the transaction Purchase of American Depositary Shares
--- -------------------------- --------------------------------------------
c) Price(s) and volume(s) Price Volume
------- -------
$13.50 22,222
------- -------
--- -------------------------- --------------------------------------------
d) Aggregated information N/A (single transaction)
- Aggregated volume
- Price
--- -------------------------- --------------------------------------------
e) Date of the transaction 27 April 2017
--- -------------------------- --------------------------------------------
f) Place of the transaction NASDAQ
--- -------------------------- --------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHSEWFMAFWSEDL
(END) Dow Jones Newswires
April 28, 2017 12:40 ET (16:40 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
